Chemed

CHE · NYSE

$516.07+$7.78 (+1.53%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $508.29

CHE analyst rating

HoldConsensus of 5 analysts over the last 12 months. 40% rate it a buy.

Strong buy0
Buy2
Hold3
Underperform0
Sell0

12-month price target · 6 analysts

Average $583.03 (+13.0% upside)

Low: $525.20
Now: $516.07
High: $682.50

Upgrades and downgrades

The latest rating actions, newest first

CHE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Sep 25, 2026	Initiates	Buy	$650.00	64%
Oppenheimer	Jul 31, 2026	Maintains	Outperform	$500.00 → $590.00	56%
RBC Capital	Jul 30, 2026	Maintains	Sector Perform	$436.00 → $548.00	57%
B of A Securities	Jul 9, 2026	Maintains	Neutral	$450.00 → $510.00	53%
RBC Capital	Apr 27, 2026	Maintains	Sector Perform	$422.00 → $436.00	57%
RBC Capital	Feb 27, 2026	Downgrade	Outperform → Sector Perform	$572.00 → $422.00	57%
Oppenheimer	Feb 27, 2026	Maintains	Outperform	$580.00 → $500.00	56%
Jefferies	Jan 22, 2026	Downgrade	Buy → Hold	$550.00 → $475.00	63%
RBC Capital	Nov 10, 2025	Maintains	Outperform	$589.00 → $572.00	57%

The case for and against

Updated Jan 19, 2026

Bull case

Chemed Corp's positive outlook is supported by strong demand growth in both its VITAS and Roto-Rooter segments. The VITAS segment, being the nation's leading hospice provider, has demonstrated significant long-term growth potential and profitability improvements, even amid competitive pressures and regulatory caps in specific markets like Florida. Additionally, projections indicate that VITAS is set to rebound in 2026, which, combined with an improving economic landscape, suggests favorable conditions for continued revenue acceleration.

Bear case

Chemed Corp faces several financial challenges projected to impact its future earnings and growth. The anticipated macroeconomic headwinds are expected to soften consumer demand for both the Roto-Rooter and VITAS segments, leading to a downward revision of FY2025 to FY2027 earnings per share estimates by 10% and lowering the price target significantly. Additionally, operational difficulties are exemplified by a 520 basis point decline in Roto-Rooter's adjusted EBITDA margin and a year-over-year decrease in lead generation, highlighting concerns over increased costs and reduced demand that could adversely affect overall profitability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.